skip to Main Content

Voruciclib Regimens Demonstrate Preliminary Potency Against KRAS-Positive Cancers

Newsfeed image, light gray text on dark gray background

The early results showed that voruciclib led to a rapid decrease in the phosphorylation of proteins that promote MYC transcription and quickly decreases phosphorylation of MYC protein on Serine 62 (Ser62), which is a site implicated in stabilizing MYC in KRAS-mutant cancers.

Treatment with voruciclib, a CDK9 inhibitor, as a monotherapy or in combination with sotorasib (AMG 510) and adagrasib demonstrated early activity in KRAS-mutant cancer cell lines, and synergistically inhibited growth of KRAS-mutant cancers in preclinical models, according to findings presented during Week 1 of the 2021 AACR Virtual Annual Meeting. Read more . . .

Back To Top